Artelo Biosciences' ART27.13 Shows Promise in Treating Chemotherapy-Induced Neuropathy — Artelo Biosciences, Inc.

Event summary

Artelo Biosciences' ART27.13 reduced neuropathic pain behaviors in a nonclinical model of paclitaxel-induced peripheral neuropathy.
Interim CAReS Phase 2 trial results showed mean weight gain of over 6% for participants receiving the top dose of ART27.13.
ART27.13 is being evaluated in the Cancer Appetite Recovery Study (CAReS) for cancer-related anorexia cachexia syndrome (CACS).
The study was presented at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium.

The big picture

Artelo Biosciences' positive results with ART27.13 in treating chemotherapy-induced neuropathy highlight the growing interest in cannabinoid receptor agonists for cancer supportive care. The company's focus on modulating lipid-signaling pathways positions it within a competitive landscape of biopharmaceutical firms targeting unmet needs in oncology. With no FDA-approved treatments currently available for CACS, ART27.13's potential to address multiple symptoms could make it a key player in this space.

What we're watching

Clinical Translation: Whether ART27.13's analgesic potential in nonclinical settings translates into clinical benefits for cancer patients.
Regulatory Pathway: The pace at which Artelo can secure regulatory approvals for ART27.13 given the unmet medical need in CACS.
Market Opportunity: How broader applications in cancer supportive care beyond appetite stimulation could expand ART27.13's market potential.